Q3 2024 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Boosted by Leerink Partnrs

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Leerink Partnrs lifted their Q3 2024 EPS estimates for shares of Edwards Lifesciences in a report issued on Friday, April 26th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings per share of $0.71 for the quarter, up from their prior forecast of $0.70. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.71 EPS and Q1 2025 earnings at $0.72 EPS.

EW has been the subject of a number of other research reports. Royal Bank of Canada boosted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Oppenheimer boosted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Piper Sandler upped their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Edwards Lifesciences Price Performance

NYSE:EW opened at $86.43 on Monday. Edwards Lifesciences has a 12-month low of $60.57 and a 12-month high of $96.12. The firm has a market cap of $52.02 billion, a price-to-earnings ratio of 37.25, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company’s 50-day moving average is $90.28 and its two-hundred day moving average is $78.95. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the completion of the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently modified their holdings of EW. DSM Capital Partners LLC acquired a new position in Edwards Lifesciences in the 4th quarter worth $28,000. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $34,000. Riverview Trust Co purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $34,000. Pingora Partners LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $38,000. Finally, Operose Advisors LLC boosted its holdings in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.